slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 40,291-40,320
Pages 1,935
Rows per page 30
Slide function
40,291-40,320 of 58,039
45
The slide uses a waterfall chart to decompose revenue growth by channel/segment.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
46
The slide uses a table to compare H1 2023 vs H1 2022, followed by bulleted commentary on margin dilution and CAPEX increases.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
48
The chart uses a waterfall bridge to decompose revenue growth by channel (Retail, Wholesale, Royalties).Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
49
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
51
The slide uses a waterfall chart to decompose revenue changes by channel.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
52
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
54
The slide uses a waterfall chart to bridge revenue between H1 2022 and H1 2023, highlighting contributions from Retail, Wholesale, and Royalties.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
55
The slide uses a high-fashion image as a visual anchor for the segment.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
57
Includes a waterfall chart for revenue growth and a summary table for operating income and CAPEX.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
58
The table highlights key income statement metrics including revenue, margins, and net income.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
59
The table compares standard H1 2023/2022 figures with an adjusted H1 2023 column.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
61
Values are in millions of Euros (€M).Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
13
The slide displays 12 bar charts representing log2(fold change) for specific genes across individual patients.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Includes error bars representing standard error of the mean; data points are plotted over 42 days.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The slide highlights a favorable safety profile with no serious adverse events (SAEs) or drug-related infections.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
25
The table displays adverse events occurring in 2 or more patients. Data includes patient counts and percentages for both 'All' and 'Related' adverse events.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
26
Includes a line chart showing plasma concentration over time and a table summarizing PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
38
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
09
Details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose levels.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
10
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration changes from baseline.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide highlights high completion rates and manageable adverse events, specifically noting injection site reactions (ISRs) as the most common side effect.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
25
The slide outlines the clinical trial methodology for a drug candidate in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
26
The slide details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose cohorts (25mg, 50mg, 100mg).Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
28
The table displays n (%) for categorical variables and descriptive statistics (mean, SD, median, range) for age.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
29
MAD likely stands for Multiple Ascending Dose.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
31
MAD = Multiple Ascending Dose. PK = Pharmacokinetics.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
35
The slide presents two distinct visualizations: a point-range plot for longitudinal data and a waterfall plot for individual subject response.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit